Sales Contract and Pricing Specialist
About the job
- A bachelor's degree or equivalent in Business Administration or a related field.
- At least 2 years of relevant career experience in contract management, pricing, or sales administration.
- Demonstrated self-starting behavior, proactiveness, and initiative.
- Accuracy and attention to detail.
- Business acumen and ability to interpret data to make effective recommendations.
- Problem-solving ability to determine an appropriate course of action and follow through to completion.
- Advanced knowledge and skill in Microsoft Office applications.
- Project management skills and ability to quickly assimilate information from diverse sources.
- Strong written, verbal, and presentation communication skills.
- Teamwork, sense of urgency, and time management skills.
- French language skills are required.
- Review and timely renew commercial customer contract documentation, ensuring compliance with AtriCure terms and conditions.
- Maintain the contract repository and related information in the shared database, CRM system, and other software applications.
- Create sales quotations and customer price lists aligned with national pricing, and execute pricing strategies to maximize customer value, market competitiveness, and profitability.
- Coordinate with Sales Directors and Regional Sales Managers on new sales tenders and renewals ahead of expiration; review tender terms and conditions and ensure timely, accurate submission.
- Coordinate with the AtriCure legal team on contract terms and conditions and obtain advice on terms that deviate from AtriCure's standard terms.
- Perform financial and commercial analysis and maintain administrative accuracy.
- Evaluate, identify, and drive initiatives to improve contracting and contract review processes, and maintain accurate contract and signing status in the contract repository.
- Provide regular reports and metrics on contract completion status, project milestones, and progress, and create presentations as needed.
- Perform additional duties as assigned.
- Experience in MedTech, healthcare, tenders, or public procurement.
- Experience with pricing analysis.
- Familiarity with contract lifecycle management.
- Exposure to commercial contracting in EMEA.
- Advanced Excel and data analysis capability.
- Experience working with CRM, ERP, or pricing systems.
- Ability to interpret performance against commercial incentives.
- Familiarity with legal and finance review workflows.
About the company
AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Mason, Ohio
Founded
1994
Get referred to AtriCure
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $153.6 million, and management raised full-year guidance.
- BoxX-NoAF enrollment surpassed 500 patients in July 2026, ahead of schedule.
- cryoXT launched in 2025 and should contribute more meaningfully in late 2026.
What critics are saying
- MIS ablation faces pulsed-field ablation cannibalization; Q1 2026 revenue there fell 25%.
- Gross margin dips below 77% in Q3 2026 as the new plant ramps.
- If BoxX-NoAF or LeAAPS miss, AtriCure loses its 2030 $1 billion thesis.
What makes AtriCure unique
- AtriCure owns a surgical AFib niche spanning ablation, appendage management, and cryoanalgesia.
- cryoSPHERE MAX and EnCompass drove Q2 2026 growth, highlighting surgeon adoption.
- BoxX-NoAF and LeAAPS create label-expansion optionality unavailable to catheter ablation rivals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Wellness Program
401(k) Company Match
Parental Leave
Pet Insurance
Employee Stock Purchase Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%AtriCure's Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on 8 September 2026 at $55 per share, according to an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan established in February 2026. Privitera retains approximately 147,000 shares in the medical device company, valued at $7.9 million based on the 8 September closing price of $53.73. The stock has risen 49% over the preceding 12 months. AtriCure, which makes specialised devices for cardiac tissue treatment, reported trailing twelve-month revenue of $569.6 million and net income of $10.6 million. The company has a market capitalisation of $2.7 billion.
AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.
AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.
AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.
AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.